Suchergebnisse - "Dangond, Fernando"

PubPharm (121)

1

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis : Contemporary Perspectives

enthalten in: Neurology and therapy | 2024

von Freedman, M. | Coyle, P. | Hellwig, K. | +8

2

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives

enthalten in: Neurology and Therapy | 2024

von Freedman, M. | Coyle, P. | Hellwig, K. | +8

3

Cladribine regimen for treating progressive forms of Multiple Sclerosis

enthalten in: Europäisches Patentamt | 2023

von DANGOND FERNANDO | DOTZAUER MATTHIAS

4

Cladribine regimen for treating progressive forms of Multiple Sclerosis

enthalten in: Europäisches Patentamt | 2023

von DANGOND FERNANDO | DOTZAUER MATTHIAS

5

The effect of cladribine tablets in people with more active multiple sclerosis : a plain language summary

enthalten in: Neurodegenerative disease management | 2022

von Vermersch, P. | Galazka, A. | Dangond, F. | +4

6

Disease stability over five years in people with multiple sclerosis treated with cladribine tablets : a plain language summary

enthalten in: Neurodegenerative disease management | 2022

von Giovannoni, G. | Comi, G. | Rammohan, K. | +4

7

Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years : a plain language summary

enthalten in: Neurodegenerative disease management | 2022

von Stefano, N. | Sormani, M. | Giovannoni, G. | +6

8

Determination of a clinically effective evobrutinib dose : Exposure-response analyses of a phase II relapsing multiple sclerosis study

enthalten in: Clinical and translational science | 2022

von Papasouliotis, O. | Mitchell, D. | Girard, P. | +2

9

Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets : a plain language summary

enthalten in: Neurodegenerative disease management | 2022

von Oh, J. | Walker, B. | Giovannoni, G. | +6

CommentOn: Mult Scler J Exp Transl Clin. 2021 Jul 13;7(3):20552173211024298. - PMID 34345436

10

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo : The CLARITY and CLARITY Extension studies

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2022

von De Stefano, N. | Sormani, M. | Giovannoni, G. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]